| 前收市價 | 5.07 |
| 開市 | 5.11 |
| 買盤 | 5.25 x 100 |
| 賣出價 | 5.37 x 100 |
| 今日波幅 | 5.01 - 5.37 |
| 52 週波幅 | 3.49 - 8.35 |
| 成交量 | |
| 平均成交量 | 148,373 |
| 市值 | 340.825M |
| Beta 值 (5 年，每月) | 1.27 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -1.49 |
| 業績公佈日 | 2024年5月09日 - 2024年5月13日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 21.60 |
ZacksMeiraGTx Holdings PLC (MGTX) Reports Q4 Loss, Misses Revenue Estimates
MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of -2.17% and 79.86%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
ZacksStrength Seen in Lifecore Biomedical (LFCR): Can Its 16.0% Jump Turn into More Strength?
Lifecore Biomedical (LFCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
BenzingaMeiraGTx's Investigational Drug Shows Improved Symptoms In Radiation-Induced Oral Dryness
MeiraGTx Holdings plc (NASDAQ: MGTX) released data from the completed Phase 1 AQUAx study of AAV2-hAQP1 for grade 2/3 radiation-induced xerostomia (RIX), which includes the final 12-month data from all bilaterally treated participants. Xerostomia refers to the sensation of oral dryness, which can result from diminished saliva production. Clinically meaningful improvements in xerostomia symptoms were observed, measured by two different xerostomia PROs demonstrated across unilaterally and bilatera
